The global diabetes injection pens market is projected to grow at a CAGR of approximately 7% through 2028. Market expansion ...

Parabilis Medicines raised $305 million in a Series F round led by RA Capital, Fidelity and Janus Henderson, with crossover ...

Pill versions of the successful GLP1 drugs from Novo Nordisk and Eli Lilly will likely be on the market in 2026’s first half.

ASN Kidney Week, held in November, featured leading-edge science in kidney care, with evidence supporting new drugs to treat ...

Novo Nordisk faces slowing growth, competition, regulatory risks, and Wegovy pricing pressure, with DCF showing fair ...

As 2026 begins, a slate of high-stakes clinical readouts—from a pivotal study of Novartis’ cardiovascular candidate ...

Federal health officials slash recommended childhood vaccinations under Trump’s directive; Novo Nordisk launched weight loss ...

Encellin, a biotechnology company pioneering Encapsulated Cell Replacement Therapy (ENCRT), today announced interim clinical results from its ongoing Phase 1 investigational trial (NCT06408311) in ...

Obesity and diabetes treatment is undergoing a revolution with the advent of GLP-1 drugs, which help manage weight, control ...

Rare Pediatric Disease Priority Review Voucher (PRV) granted by FDA at approval to be transferred from Sentynl Therapeutics to Cyprium Cyprium eligible to receive tiered royalties and up to $129 milli ...

Novo Nordisk carries a Zacks Rank #5 (Strong Sell), whereas Amgen carries a Zacks Rank #3 (Hold) at present, which makes AMGN ...

Detailed price information for Tonix Pharm Holdings (TNXP-Q) from The Globe and Mail including charting and trades.